SCHEMBL360069

SCHEMBL360069

O=C(O)NCCC1=NN(CC2CC2)C(=O)C1

nearest known ligand 0.32

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
KMT2A Q03164 1/20 0.32
THRB P10828 1/20 0.31
ITGB3 P05106 1/20 0.30
ITGA2B P08514 1/20 0.30
TP53 P04637 1/20 0.30
NOTUM Q6P988 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL361567 0.94 POLB (0.35) MEN1POLBKMT2A
SCHEMBL360469 0.94 KMT2A (0.37) MEN1POLBKMT2A
SCHEMBL360213 0.93 KMT2A (0.39) MEN1POLBKMT2A
SCHEMBL14953072 0.89 P2RX7 (0.32)
SCHEMBL360190 0.88 THRB (0.33) POLBKMT2ATHRBITGB3ITGA2B
SCHEMBL360067 0.83 RORC (0.36) MEN1POLBKMT2ATHRBITGB3
SCHEMBL14953141 0.81 OPRM1 (0.34) MEN1POLBKMT2A
SCHEMBL360133 0.79 THRB (0.32) POLBTHRBTP53
SCHEMBL361730 0.78 THRB (0.49) MEN1POLBKMT2ATHRBTP53
SCHEMBL359250 0.77 ALDH1A1 (0.56) POLBKMT2ATHRBTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11312688-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-04-26 US disclosed
US-20200308119-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2020-10-01 US disclosed
US-10723703-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2020-07-28 US disclosed
US-20190084938-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2019-03-21 US disclosed
US-10183913-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2019-01-22 US disclosed
US-10087146-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-10-02 US disclosed
US-20180273489-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2018-09-27 US disclosed
US-20170217902-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2017-08-03 US disclosed
US-9663472-B2 Pyrazole compound SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-05-30 US disclosed
EP-2594559-B1 PYRAZOLE COMPOUND SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2016-02-24 EP disclosed
US-20140315971-A1 PYRAZOLE COMPOUND NEUROINNOVATECH APS (DK) 2014-10-23 US disclosed
US-8809383-B2 Pyrazole compound DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-08-19 US disclosed
US-20140031406-A1 PYRAZOLE COMPOUND DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-01-30 US disclosed
EP-2594559-A1 PYRAZOLE COMPOUND Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-05-22 EP disclosed
WO-2012008528-A1 PYRAZOLE COMPOUND 大日本住友製薬株式会社 (JP) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315971-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A MEN1 3975/4885POLB 4307/4885KMT2A 2238/4885
US-10183913-B2 Pyrazole compound HTR2C, HTR3B, HTR3A MEN1 3975/4885POLB 4307/4885KMT2A 2238/4885
US-20170217902-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A MEN1 3975/4885POLB 4307/4885KMT2A 2238/4885
US-11312688-B2 Pyrazole compound HTR2C, HTR3B, HTR3A MEN1 3975/4885POLB 4307/4885KMT2A 2238/4885
US-20200308119-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A MEN1 3975/4885POLB 4307/4885KMT2A 2238/4885
US-10723703-B2 Pyrazole compound HTR2C, HTR3B, HTR3A MEN1 3975/4885POLB 4307/4885KMT2A 2238/4885
US-20180273489-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A MEN1 3975/4885POLB 4307/4885KMT2A 2238/4885
US-20190084938-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A MEN1 3975/4885POLB 4307/4885KMT2A 2238/4885
US-10087146-B2 Pyrazole compound HTR2C, HTR3B, HTR3A MEN1 3975/4885POLB 4307/4885KMT2A 2238/4885
US-20140031406-A1 PYRAZOLE COMPOUND HTR2C, HTR3B, HTR3A MEN1 3975/4885POLB 4307/4885KMT2A 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.